NG004
Drugrepeated intrathecal injections of NG004 within 30 days
NCT Number: NCT07840196
This is a randomized, double-blind, placebo controlled, multicenter trial of NG004 in patients with acute traumatic incomplete cervical SCI. The trial will evaluate the safety and tolerability, PK, and effects on motor function and daily life functioning of NG004 compared with placebo.
Interested in participating?
Request Info18 year–75 year
All sexes
Interventional
Phase 1
Klinik für Querschnittgelähmte, Klinikum Bayreuth, Bayreuth, Germany
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
repeated intrathecal injections of NG004 within 30 days
repeated intrathecal injections of Placebo within 30 days
Time frame: From treatment start up to 6 months
Time frame: From treatment start up to 6 months
Time frame: Baseline to 6 months
The ISNCSCI bilateral Upper Extremity Motor Score (UEMS) is determined by examining the muscle function within each of the 5 myotomes encompassing arm and hand function on each side of the body. A score ranging from 0 to 5 can be given to each myotome tested resulting in a maximum score of 50. Higher values indicate better recovery
Time frame: Month 6
The SCIM III questionnaire self-care score assesses activities of daily living including feeding, bathing, dressing, and grooming. The self-care score ranges 0-20. The higher scores correspond to better ability to carry out the self-care activities.
Time frame: Month 6
The GRASSP is a validated clinical measure of hand function in tetraplegic patients and can assess changes in impairment over time. The GRASSP (Version 2) consists of 4 subtests. The subtest strength (manual muscle testing of 10 muscles of the upper limb) and the subtest prehension performance (grasping test with 4 activities of daily living) will be performed.
Time frame: Month 6
WISCI II is a 21-item hierarchical scale of walking based on physical assistance, need of braces and devices, with an ordinal range from 0 (unable to walk) to 20 (walking without assistance for at least 10 meters).
Time frame: Month 6
10mWT is a quantitative measurement of lower extremity function. The patient shall walk a set distance (10 meters) at preferred walking speed. The distance covered, the time taken, and the assistance used will be recorded.
Time frame: Month 6
6MWT is a test used to determine the locomotor performance. Patients are instructed to walk as far as possible during 6 minutes, with rests being taken whenever required. The distance covered in time or until abort, the walking time until abort, and the number of rests are assessed.
Time frame: Baseline up to 6 months
The various lung parameters will include Forced Vital Capacity (FVC), Forced Expiratory volume in one second (FEV1) and peak expiratory flow (PEF).
FVC measures volume in Litter delivered during an expiration made as forcefully and completely as possible starting from full inspiration.
FEV1 assess the volume measured in Litter delivered in the first second of a FVC maneuver. PEF measures highest flow delivered during FVC maneuver (L/min).
Time frame: Baseline up to 6 months
Effect on respiratory function measuring respiratory muscle strength: Maximal Inspiratory Pressure [MIP] and Maximum Expiratory Pressure [MEP]. MIP is assessed as the pressure (in cmH2O) during inhalation against a completely occluded airway and is used to evaluate inspiratory muscle strength. MEP a measure of the strength of expiratory muscles, obtained by having the patient exhale as strongly as possible against a resistance. It is assessed as the pressure (in cmH2O) during exhaling.
Time frame: Baseline to 6 months
MRI scans of the spine will be used to characterize the extent of the lesion from the SCI by assessing morphological measures. Analyses of lesion parameters as preserved tissue bridges, lesion volume, lesion length, lesion width and spinal cord atrophy will be performed. Spinal cord atrophy is measured by calculating the cross-sectional area (CSA) of the spinal cord. Quantitative MRI will be used to assess microstructural tissue integrity, as assed by diffusion tensor imaging and quantitative magnetization transfer saturation mapping.
Time frame: Month 6
MAS is a 6-point muscle tone assessment scale. Scores range from 0 to 4, where lower scores represent normal muscle tone and higher scores represent spasticity or increased resistance to passive movement.
Time frame: Month 6
Neuropathic pain will be assessed by the European Multicenter Study About Spinal Cord Injury (EMSCI) Neuropathic Pain Assessment Form (NePAF), which is based on a structured interview using rating scales, and includes specific assessment of the SCI-associated neuropathic pain in terms of location, quality and severity. The pain intensity is rated with an 11-point numeric rating scale with 0 indicating no pain and 10 indicating the worst imaginable pain.
Interested in participating?
Request InfoNovaGo Therapeutics AG
Industry
A Randomized, Double-blind, Placebo Controlled Clinical Trial to Investigate the Human Monoclonal Antibody NG004 in Acute, Incomplete Cervical Spinal Cord Injury (SCI) Patients
Acronym: SPROUT-2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06817577
Acute Spinal Cord Injury (SCI), Central Nervous System Diseases
Bayreuth, Germany
View Trial DetailsNCT07733401
Acute Spinal Cord Injury (SCI), Central Nervous System Diseases
Beijing, Beijing Municipality, China
View Trial DetailsNCT07090473
Acute Spinal Cord Injury (SCI), Acute Spinal Cord Injury of Traumatic Origin (tSCI)
San Francisco, California, United States
View Trial DetailsNCT06677229
Acute Spinal Cord Injury (SCI)
Córdoba, Spain
View Trial Details